Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 13/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.38 |
| ▸ | AGXT | P21549 | 8/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20390770 | 0.81 | EGLN1 (0.32) | EGLN1 | |
| SCHEMBL13623262 | 0.81 | NOS3 (0.36) | EGLN1 | |
| SCHEMBL13615808 | 0.78 | CPB2 (0.36) | EGLN1 | |
| SCHEMBL1598470 | 0.76 | LMNA (0.49) | EGLN1 | |
| SCHEMBL13623581 | 0.75 | GABRP (0.36) | EGLN1 | |
| SCHEMBL20390799 | 0.75 | GRIN2D (0.38) | — | |
| Hydrochloric Acid SCHEMBL5038672 | 0.75 | LMNA (0.48) | IDO1EGLN1AGXT | |
| SCHEMBL5014445 | 0.73 | KCNJ1 (0.54) | EGLN1 | |
| SCHEMBL17023389 | 0.72 | GRIA1 (0.39) | — | |
| SCHEMBL13623091 | 0.72 | NOS3 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231298-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8383785-B2 | Anti-bacterial activity of 9-hydroxy derivatives of 6,11-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| CN-102088848-A | Antibacterial activity of 6, 11-bicyclic 9-hydroxy derivatives | ENANTA PHARM INC | 2011-06-08 | — | — | CN | disclosed |
| WO-2009137737-A2 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6, 11-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090281050-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231298-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | CYP8B1, SI, CYP51A1 | IDO1 623/4885EGLN1 388/4885AGXT 2210/4885 |
| US-20090281050-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | CYP8B1, SI, CYP51A1 | IDO1 623/4885EGLN1 388/4885AGXT 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.